Merck, Inc.
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT05705349
- Locations
- 🇺🇸
Pueblo Family Physicians ( Site 5674), Phoenix, Arizona, United States
🇺🇸Pacific Oaks Medical Group ( Site 5681), Beverly Hills, California, United States
🇺🇸Ruane Clinical Research Group, Inc ( Site 5658), Los Angeles, California, United States
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT05700734
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 518
- Registration Number
- NCT05696080
- Locations
- 🇨🇱
Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010), Talca, Maule, Chile
🇨🇦Clinique de médecine Urbaine du Quartier Latin ( Site 0111), Montreal, Quebec, Canada
🇺🇸Mid Hudson Medical Research ( Site 0008), New Windsor, New York, United States
A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT05673460
- Locations
- 🇯🇵
National Cancer Center Hospital East ( Site 0002), Kashiwa, Chiba, Japan
🇯🇵Kyushu University Hospital ( Site 0008), Fukuoka, Japan
🇯🇵Chiba Cancer Center ( Site 0005), Chiba, Japan
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1594
- Registration Number
- NCT05665595
- Locations
- 🇦🇷
Clinica Adventista Belgrano-Oncology ( Site 0211), Caba, Argentina
🇨🇳West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667), Cheng Du, Sichuan, China
🇺🇸The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123), Los Angeles, California, United States
A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05656040
- Locations
- 🇺🇸
Advanced Pharma CR, LLC ( Site 0006), Miami, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0002), Knoxville, Tennessee, United States
🇺🇸Velocity Clinical Research, New Smyrna Beach ( Site 0003), Edgewater, Florida, United States
Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT05633992
- Locations
- 🇯🇵
PS Clinic ( Site 1002), Fukuoka, Japan
🇯🇵Medical Corporation Shinanokai Shinanozaka Clinic ( Site 1006), Shinjuku-ku, Tokyo, Japan
🇯🇵Heishinkai Medical Group ToCROM Clinic ( Site 1004), Shinjuku-ku, Tokyo, Japan
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 553
- Registration Number
- NCT05631093
- Locations
- 🇬🇧
Brighton and Sussex University Hospitals NHS Trust ( Site 4104), East Sussex, Brighton And Hove, United Kingdom
🇨🇭University Hospital Basel-Infectiology ( Site 4002), Basel, Basel-Stadt, Switzerland
🇿🇦Wentworth Hospital ( Site 3904), Durban, Kwazulu-Natal, South Africa
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
- Conditions
- Interventions
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 514
- Registration Number
- NCT05630755
- Locations
- 🇺🇸
North Texas Infectious Diseases Consultants, P.A ( Site 1404), Dallas, Texas, United States
🇨🇱Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 2205), Temuco, Araucania, Chile
🇨🇱Universidad de Chile - Hospital Clínico Universidad de Chile-Inmunologia Alergia y VIH ( Site 2200), Santiago, Region M. De Santiago, Chile
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT05624554
- Locations
- 🇺🇸
Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States
🇺🇸Clermont Oncology Center ( Site 5224), Clermont, Florida, United States
🇺🇸Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States